|
Common Stock - Additional Information (Detail) (USD $)
In Millions, except Share data, unless otherwise specified |
0 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 22, 2010
|
Oct. 31, 2010
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Mar. 27, 2012
|
Mar. 21, 2012
|
Dec. 31, 2013
2010 Performance incentive plan [Member]
|
Dec. 31, 2012
2010 Performance incentive plan [Member]
|
Dec. 31, 2013
Stock options [Member]
Minimum [Member]
|
Dec. 31, 2013
Stock options [Member]
Maximum [Member]
|
Dec. 31, 2013
Stock options [Member]
Employees and consultants [Member]
Minimum [Member]
|
Dec. 31, 2013
Stock options [Member]
Employees and consultants [Member]
Maximum [Member]
|
Dec. 31, 2013
Stock options [Member]
Board of directors [Member]
Minimum [Member]
|
Dec. 31, 2013
Stock options [Member]
Board of directors [Member]
Maximum [Member]
|
Dec. 31, 2013
Stock options [Member]
2010 Performance incentive plan [Member]
|
Dec. 31, 2013
Restricted stock unit awards [Member]
|
Dec. 31, 2013
Restricted stock unit awards [Member]
2010 Performance incentive plan [Member]
|
Dec. 31, 2013
MLV [Member]
|
Jun. 30, 2013
MLV [Member]
|
Oct. 31, 2010
Stock warrants [Member]
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||
| Common stock, shares authorized | 50,000,000 | 25,000,000 | |||||||||||||||||||
| Common stock, par value | $ 0.001 | $ 0.001 | |||||||||||||||||||
| Preferred stock, shares authorized | 5,000,000 | ||||||||||||||||||||
| Preferred stock, par value | $ 0.001 | ||||||||||||||||||||
| Issuance of common shares | 3,174,602 | 14,707,886 | 14,656,916 | 4,165,000 | 0 | ||||||||||||||||
| Common stock, purchase price | $ 15.75 | $ 12.00 | |||||||||||||||||||
| Public offering, unit description | Each unit consisting of one share of our common stock and one-half (1/2) of one warrant | ||||||||||||||||||||
| Net amount received from public offering | $ 50.0 | $ 53.8 | |||||||||||||||||||
| Exercise price warrants | $ 20 | $ 20 | |||||||||||||||||||
| Black-Scholes value of the warrant on an assumed risk-free rate | 1.25% | 0.96% | 1.70% | 1.17% | |||||||||||||||||
| Black-Scholes value of the warrant on volatility | 86.00% | 95.00% | 76.00% | 75.00% | |||||||||||||||||
| Black-Scholes value of the warrant expected life | 5 years 9 months 18 days | 5 years 10 months 24 days | 5 years 10 months 24 days | 5 years | |||||||||||||||||
| Net proceeds to OncoGenex, from the sale of the units | 46.7 | ||||||||||||||||||||
| Allocation to common shares | 32.3 | ||||||||||||||||||||
| Allocation to warrant liability | 15.4 | ||||||||||||||||||||
| Underwriting discounts and commissions and other offering expenses allocated to the value of warrants | 1 | ||||||||||||||||||||
| Warrants outstanding | 1,587,301 | ||||||||||||||||||||
| Exercisable warrants expiring date | Expiring in October 2015 | ||||||||||||||||||||
| Number of warrants exercised | 0 | 0 | 0 | ||||||||||||||||||
| Additional issuance of common stock | 624,750 | ||||||||||||||||||||
| Additional issuance of common stock per share | $ 12.00 | ||||||||||||||||||||
| Gross offering amount from the public offering | 57.5 | ||||||||||||||||||||
| Common stock Sales Agreement aggregate offering amount | $ 25 | ||||||||||||||||||||
| Common stock Sales Agreement aggregate commission in percentage | 3.00% | ||||||||||||||||||||
| Number of optioned common shares, option exercises | 3,475 | 117,347 | 56,228 | ||||||||||||||||||
| Restricted stock unit settlements | 47,495 | 0 | 0 | ||||||||||||||||||
| Common shares reserved for issuance under various plans | 2,380,133 | ||||||||||||||||||||
| Common shares reserved for options currently outstanding | 1,006,991 | 356,589 | |||||||||||||||||||
| Common shares available for future option grants | 1,016,553 | 1,265,857 | |||||||||||||||||||
| Award vesting period | 3 years | 4 years | 1 year | 3 years | 4 years | ||||||||||||||||
| Award expiration period | 7 years | 10 years | |||||||||||||||||||
| Warrants expiration date | 2015-10 | ||||||||||||||||||||